Please provide your email address to receive an email when new articles are posted on . The rate of exacerbation was 46.8% in the group using metformin and 63% in the group not using metformin. The ...

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic phenotype. Some 20% to 40% of COPD patients have elevated blood eosinophil counts ...

The 2026 version of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy report has been published. Key updates in the report were highlighted in a presentation by Claus F ...

Mepolizumab significantly reduces exacerbations in patients with asthma and concurrent chronic obstructive pulmonary disease (COPD), with a 55% reduction in COPD exacerbations post initiation. A ...

New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of life in patients with eosinophilic chronic obstructive pulmonary disease (COPD ...

COPD experimental therapy 9MW1911 reduced moderate to severe exacerbations in a Phase 2a trial, showing a favorable safety ...

Please provide your email address to receive an email when new articles are posted on . After using an antidepressant, the risk for pneumonia and COPD exacerbations went up. Discontinuing ...

Adding mepolizumab to inhaled triple therapy significantly improved exacerbation outcomes compared with placebo in adults with chronic obstructive pulmonary disease (COPD), based on data from the ...

Hospitalizations for bronchiectasis exacerbations are associated with poorer in-hospital outcomes than those for chronic obstructive pulmonary disease or asthma exacerbations.

Findings showed a statistically significant and clinically meaningful reduction in the annualized rate of moderate to severe exacerbations with mepolizumab vs placebo. Mepolizumab was found to ...

—Theses investigators found an increased risk for both individual and composite cardiovascular events following exacerbations of COPD, with sustained risk after 1 year regardless of severity. Reviewed ...

Almost 16 million adults have COPD in the United States and about 3 in 4 people with this condition have at least one flare (exacerbation) a year, cites a review. But you don’t have to sit and wait ...